News | July 08, 2025
Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
The company showcased three core programs developed through this platform
The company showcased three core programs developed through this platform
mRNA-1010 demonstrated superior relative vaccine efficacy
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The demand in Africa for COVID-19 vaccines has declined
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Subscribe To Our Newsletter & Stay Updated
